MedTrace Logo

Observing Metabolism of EPA With Consideration of Genetics And Sex

NCT06975241 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2026-02-27

No results posted yet for this study

Summary

The goal of this clinical study is to learn how fast EPA is converted to other molecules, including DHA, with consideration of biological sex and genetics in healthy humans.

The main questions it aims to answer are:

* How fast is EPA converted to DHA in blood, and is the conversion rate affected by sex and a specific genotype we previously identified?
* How do sex and the specific genotypes affect blood DHA levels and other products of DHA in response to dietary EPA?
* How fast does dietary EPA replace blood EPA and other omega-3 fatty acids, and is the rate affected by sex and genotype?

Participants will be asked to take EPA supplements for 12 weeks and provide a series of venous blood samples over the study duration.

Conditions

  • Healthy
  • Omega 3
  • Metabolism, Lipids

Interventions

DIETARY_SUPPLEMENT

EPA 2.4g/day

EPA from fish oil will be supplemented to an equal number of males and females for 12 weeks.

Sponsors & Collaborators

  • University of Toronto

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-29
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06975241 on ClinicalTrials.gov